PX1 Research has announced the release of new batches of Retatrutide and Tirzepatide research peptides, manufactured in the United States under current Good Manufacturing Practice (cGMP) standards. Each batch is verified through high-performance liquid chromatography (HPLC) and comes with a Certificate of Analysis confirming purity of 99% or above. This release expands the company's catalog of dual-incretin peptides and underscores its commitment to quality and traceability.
The manufacturing process takes place in USA cGMP-certified facilities, which adhere to stringent regulations governing facility conditions, equipment qualification, personnel training, and documentation. With over 16 years of peptide manufacturing expertise, PX1 Research ensures that its production methods meet rigorous standards. For research institutions, the source and verification of peptides are crucial for maintaining data integrity across experiments. Domestic cGMP manufacturing provides a traceable chain of production documentation, which is essential for compliance and reproducibility.
Each batch undergoes a seven-stage testing protocol before shipment. HPLC batch verification is the analytical cornerstone, separating peptide compounds to quantify purity with high resolution. The protocol also includes checks for endotoxin contamination, amino acid sequence integrity, and mass accuracy through spectrometric analysis. This comprehensive approach results in batch-specific Certificates of Analysis, allowing researchers to verify the quality of their specific shipment rather than relying on generalized lot data. HPLC is a standard method for pharmaceutical-grade testing, and applying it at the batch level ensures that every shipment is documented with its own test results.
Retatrutide and Tirzepatide are significant in metabolic and endocrine research. Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Retatrutide is a triple agonist that also engages the glucagon receptor. The structural complexity of these molecules demands precise manufacturing, as minor deviations can affect receptor binding. By offering both peptides under the same high standards, PX1 Research enables research teams to source compounds with comparable documentation, which is beneficial for comparative studies or parallel study arms.
The newly released batches are available for procurement through PX1 Research's catalog. The Retatrutide offering can be accessed at px1research.com, and the Tirzepatide offering is also available at px1research.com. Certificates of Analysis for current batch numbers are provided alongside each product listing.
PX1 Research is a USA-based manufacturer of research-grade peptides, producing compounds in cGMP-certified facilities. The company applies over 16 years of manufacturing expertise and employs a seven-stage quality testing protocol, including HPLC batch verification, to ensure purity levels of 99% or above for every batch shipped.
